If you need help accessing our website, call 855-698-9991
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Anam Qureshi, MD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialties: Ophthalmology, Cornea External Disease & Refractive Surgery
  • Treats: Adults
  • Languages: English, Urdu
  • Phone: 212-448-0101
View Locations

Conditions and Treatments

Conditions
  • abnormal eye pressure
  • astigmatism
  • blepharitis
  • blurred vision
  • cataract
  • chalazion
  • cloudy vision
  • conjunctivitis
  • corneal abrasion
  • corneal disease
  • corneal ulcer
  • diabetes
  • diabetic retinopathy
  • dislocated intraocular lens
  • distorted vision
  • double vision
  • dry eye disease
  • excessive tearing
  • exfoliation syndrome
  • eye floater
  • eye infection
  • eye injury
  • eye pain
  • eye redness
  • facial spasm
  • fuchs' dystrophy
  • glaucoma
  • halo vision
  • hyperopia
  • hyperthyroidism
  • keratoconus
  • lazy eye
  • macular degeneration
  • meibomian gland dysfunction
  • myopia
  • night blindness
  • ocular herpes
  • presbyopia
  • pterygium
  • refractive error
  • rosacea
  • sicca syndrome
  • stye
  • sudden loss of vision
  • thyroid disorder
  • traumatic fracture
  • trichiasis
  • uveitis
  • watery eye
Treatments
  • cataract removal surgery
  • color vision test
  • corneal collagen cross-linking
  • corneal transplant
  • descemet membrane endothelial keratoplasty (DMEK)
  • descemet stripping automated endothelial keratoplasty (DSAEK)
  • endothelial keratoplasty
  • fixated intraocular lens
  • laser surgery
  • lasik surgery
  • photorefractive keratectomy
  • refractive surgery

Board Certifications
  • American Board of Ophthalmology - Ophthalmology, 2017
Education and Training
  • Fellowship, Emory University, Cornea, External Disease, and Refractive Surgery, 2016
  • Residency, NYU Langone Medical Center, Ophthalmology, 2015
  • MD from Jefferson Medical College, 2011

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

  • Aetna
     
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Blue Cross Blue Shield
     
    • Empire BCBS Top Tier
  • Cigna
     
    • Cigna EPO/POS
    • Cigna Medicare
    • Cigna PPO
  • Empire Blue Cross Blue Shield
     
    • Empire Blue Cross Blue Shield EPO
    • Empire Blue Cross Blue Shield HMO
    • Empire Blue Cross Blue Shield Indemnity
    • Empire Blue Cross Blue Shield MediBlue
    • Empire Blue Cross Blue Shield POS
    • Empire Blue Cross Blue Shield PPO
    • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Oxford
     
    • Oxford Freedom
    • Oxford Liberty
    • Oxford Medicare
  • UHC
     
    • UnitedHealthcare EPO
    • UnitedHealthcare HMO
    • UnitedHealthcare Medicare
    • UnitedHealthcare POS
    • UnitedHealthcare PPO
    • UnitedHealthcare Top Tier
View All Accepted Plans This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Anam Qureshi, MD does not accept insurance.

Locations and Appointments

Madison Ophthalmology PLLC

161 Madison Avenue, Ste 5SE, New York, NY 10016

Phone

212-448-0101

Fax

212-448-0116

  • A Phase 1b Trial of ZEN003694 (ZEN-3694) with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer

    Learn More
  • A Randomised Open-Label Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1 BRCA2 or PALB2 Mutations and Hormone Receptor Positive HER2-Negative (IHC 0 1+ 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

    Learn More
  • AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS

    Learn More
View All Research Studies (13)

  • Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma

    Martin-Algarra, S; Haanen, J B; Horak, C; Bhatia, S; Ribas, A; Hwu, W -J; Slingluff,, C L; Sharfman, W H; Callahan, M; Hodi, F S; Wolchok, J D; Luke, J; Young, T C; Qureshi, A; Urba, W J

    Annals of oncology. 2016 October 1; 27(Supplement):vi385

  • Jehangir, Asad; Bennett, Kyle; Fareedy, Shoaib Bilal; Rettew, Andrew; Shaikh, Bilal; Qureshi, Anam; Jehangir, Qasim; Alweis, Richard

    Case reports in gastrointestinal medicine. 2015 May ; 2015:356293

  • Shields, Carol L; Qureshi, Anam; Eagle, Ralph C Jr; Lally, Sara E; Shields, Jerry A

    Cornea. 2012 Jul ; 31(7):756-60

Read All Publications (6)